^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD22-targeted CAR-T immunotherapy

    Related drugs:
    8d
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Peking University People's Hospital | N=30 --> 50 | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    11d
    Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
    P1/2, N=93, Recruiting, Stephan Grupp MD PhD | Trial completion date: Jan 2029 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CART22 • huCART19
    28d
    CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=100, Recruiting, Beijing Tongren Hospital
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    2ms
    A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma (clinicaltrials.gov)
    P1/2, N=42, Active, not recruiting, Seattle Children's Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD22 (CD22 Molecule)
    |
    SCRI-CAR22v2
    2ms
    Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies (clinicaltrials.gov)
    P1, N=20, Recruiting, Stanford University | Trial completion date: Nov 2025 --> Jul 2026 | Trial primary completion date: Nov 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)
    2ms
    UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis (clinicaltrials.gov)
    P1, N=21, Recruiting, Nanjing IASO Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Sheba Medical Center | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Feb 2026
    Enrollment open • Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive
    3ms
    CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    3ms
    Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Tongji Hospital | Trial completion date: Oct 2027 --> Feb 2029 | Initiation date: Mar 2025 --> Feb 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    3ms
    Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (clinicaltrials.gov)
    P1, N=68, Recruiting, University of Colorado, Denver | N=20 --> 68 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19x22 CAR T
    4ms
    CD22 Redirected Autologous T Cells for ALL (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, University of Pennsylvania | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD22 (CD22 Molecule)
    4ms
    CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov)
    P1, N=53, Recruiting, University of Colorado, Denver | N=26 --> 53
    Enrollment change
    |
    CD19x22 CAR T